Journal article
Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.
Abstract
4530
Authors
Heng DYC; Doshi GK; Dutailly P; Houchard A; Lothgren M; Monnette A; Wang Y; Perrot V; Lalani A-KA
Journal
Journal of Clinical Oncology, Vol. 41, No. 16_suppl, pp. 4530–4530
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 1, 2023
DOI
10.1200/jco.2023.41.16_suppl.4530
ISSN
0732-183X